


## BTO-1

Cat. No.:	HY-112395
CAS No.:	40647-02-7
Molecular Formula:	C <sub>9</sub> H <sub>4</sub> N <sub>4</sub> O <sub>4</sub> S
Molecular Weight:	264.22
Target:	Polo-like Kinase (PLK)
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

Description	BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications [1][2].
IC <sub>50</sub> & Target	Plx1
In Vitro	BTO-1 (50 μM; 4 hours; U20S cells) results in monopolar spindles in a comparable fraction of mitotic cells. BTO-1(20 μM; 1 hour; PTK cells) shows a dose-dependent reduction in phospho-Cdc25C. BTO-1(25 μM; 1 hour; PTK cells) shows about 20 % reduction in H3 phosphorylation compared to control cells. BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring <sup>[1][2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Peters, U., et al. Probing cell-division phenotype space and Polo-like kinase function using small molecules. *Nat Chem Biol* 2, 618–626 (2006).
- [2]. Brennan IM, et al. Polo-like kinase controls vertebrate spindle elongation and cytokinesis. *PLoS One*. 2007;2(5):e409. Published 2007 May 2.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA